Eslicarbazepine acetate for partial-onset seizures

References

• Wallace H, Shorvon S, Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. Lancet352(9145), 1970–1973 (1998).
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Early identification of refractory epilepsy. N. Engl. J. Med.342(5), 314–319 (2000).
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Refractory epilepsy: mechanisms and solutions. Expert Rev. Neurother.6(3), 397–406 (2006).
   PubMedGoogle Scholar
• Brodie MJ. Antiepileptic drug therapy the story so far. Seizure19(10), 650–655 (2010).
   PubMed Web of Science ®Google Scholar
• Brodie MJ. Monostars: an aid to choosing an antiepileptic drug as monotherapy. Epilepsia40(Suppl. 6), S17–S22 (1999).
   Google Scholar
• Brodie MJ, Sills GJ. Combining antiepileptic drugs-rational polytherapy? Seizure20(5), 369–375 (2011).
   PubMed Web of Science ®Google Scholar
• Johannessen Landmark C, Johannessen SI. Pharmacological management of epilepsy: recent advances and future prospects. Drugs68(14), 1925–1939 (2008).
   PubMed Web of Science ®Google Scholar
• Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev. Neurother.10(1), 119–140 (2010).
   PubMed Web of Science ®Google Scholar
• Johannessen SI, Ben-Menachem E. Management of focal-onset seizures: an update on drug treatment. Drugs66(13), 1701–1725 (2006).
   PubMed Web of Science ®Google Scholar
• Brodie M, Covanis T, Gil-Nagel A et al. Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav.21(4), 331–341 (2011).
   PubMed Web of Science ®Google Scholar
• Almeida L, Falcao A, Maia J, Mazur D, Gellert M, Soares-da-Silva P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2–093) in healthy elderly and young subjects. J. Clin. Pharmacol.45(9), 1062–1066 (2005).
   PubMed Web of Science ®Google Scholar
• Almeida L, Nunes T, Sicard E et al. Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects. Acta Neurol. Scand.121(4), 257–264 (2010).
   PubMed Web of Science ®Google Scholar
• Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BIA 2–093). Neurotherapeutics4(1), 88–96 (2007).
   PubMed Web of Science ®Google Scholar
• Rauchenzauner M, Luef G. Update on treatment of partial onset epilepsy: role of eslicarbazepine. Neuropsychiatr. Dis. Treat.6, 723–730 (2010).
   PubMed Web of Science ®Google Scholar
• Almeida L, Soares-da-Silva P. Safety, tolerability and pharmacokinetic profile of BIA 2–093, a novel putative antiepileptic agent, during first administration to humans. Drugs RD4(5), 269–284 (2003).
   PubMedGoogle Scholar
• Ambrosio AF, Soares-da-Silva P, Carvalho CM, Carvalho AP. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2–093, and BIA 2–024. Neurochem. Res.27(1–2), 121–130 (2002).
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Gabbai AA, Hufnagel A, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res.89(2–3), 278–285 (2010).
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res.83(1), 1–43 (2009).
   PubMed Web of Science ®Google Scholar
• Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat. Rev. Drug Discov.9(1), 68–82 (2010).
   PubMed Web of Science ®Google Scholar
• French JA, Kanner AM, Bautista J et al. Efficacy and tolerability of the new antiepileptic drugs, II: treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia45(5), 410–423 (2004).
   PubMedGoogle Scholar
• Hainzl D, Parada A, Soares-da-Silva P. Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine. Epilepsy Res.44(2–3), 197–206 (2001).
   PubMed Web of Science ®Google Scholar
• McCormack PL, Robinson DM. Eslicarbazepine acetate. CNS Drugs23(1), 71–79 (2009).
   PubMed Web of Science ®Google Scholar
• Bonifacio MJ, Sheridan RD, Parada A, Cunha RA, Patmore L, Soares-da-Silva P. Interaction of the novel anticonvulsant, BIA 2–093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia42(5), 600–608 (2001).
   PubMed Web of Science ®Google Scholar
• Almeida L, Bialer M, Soares-da-Silva P. Eslicarbazepine acetate. In: The Treatment of Epilepsy (3rd Edition). Shorvon S, Perucca E, Engel J (Eds). Blackwell Publishing, Oxford, UK, 485–498 (2009).
   Google Scholar
• Parada A, Soares-da-Silva P. The novel anticonvulsant BIA 2–093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine. Neurochem. Int.40(5), 435–440 (2002).
   PubMed Web of Science ®Google Scholar
• Sierra-Paredes G, Nunez-Rodriguez A, Vazquez-Lopez A, Oreiro-Garcia T, Sierra-Marcuno G. Anticonvulsant effect of eslicarbazepine acetate (BIA 2–093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats. Epilepsy Res.72(2–3), 140–146 (2006).
   PubMed Web of Science ®Google Scholar
• Benes J, Parada A, Figueiredo AA et al. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J. Med. Chem.42(14), 2582–2587 (1999).
   PubMed Web of Science ®Google Scholar
• Sierra-Paredes G, Oreiro-Garcia MT, Vazquez-Illanes MD, Sierra-Marcuno G. Effect of eslicarbazepine acetate (BIA 2–093) on latrunculin A-induced seizures and extracellular amino acid concentrations in the rat hippocampus. Epilepsy Res.77(1), 36–43 (2007).
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E. Eslicarbazepine acetate: a well-kept secret? Epilepsy Curr.10(1), 7–8 (2010).
   PubMedGoogle Scholar
• Elger C, Bialer M, Cramer JA, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia48(3), 497–504 (2007).
   PubMed Web of Science ®Google Scholar
• Elger C, Halasz P, Maia J, Almeida L, Soares-da-Silva P. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group Phase III study. Epilepsia50(3), 454–463 (2009).
   PubMed Web of Science ®Google Scholar
• Gil-Nagel A, Lopes-Lima J, Almeida L, Maia J, Soares-da-Silva P. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol. Scand.120(5), 281–287 (2009).
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res.73(1), 1–52 (2007).
   PubMed Web of Science ®Google Scholar
• Almeida L, Potgieter JH, Maia J, Potgieter MA, Mota F, Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur. J. Clin. Pharmacol.64(3), 267–273 (2008).
   PubMed Web of Science ®Google Scholar
• Fontes-Ribeiro C, Nunes T, Falcao A et al. Eslicarbazepine acetate (BIA 2–093): relative bioavailability and bioequivalence of 50 mg/ml oral suspension and 200mg and 800mg tablet formulations. Drugs RD6(5), 253–260 (2005).
   PubMedGoogle Scholar
• Almeida L, Minciu I, Nunes T et al. Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy. J. Clin. Pharmacol.48(8), 966–977 (2008).
   PubMed Web of Science ®Google Scholar
• Maia J, Almeida L, Falcao A et al. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int. J. Clin. Pharmacol. Ther.46(3), 119–130 (2008).
   PubMed Web of Science ®Google Scholar
• Almeida L, Soares-da-Silva P. Safety, tolerability, and pharmacokinetic profile of BIA 2–093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. J. Clin. Pharmacol.44(8), 906–918 (2004).
   PubMed Web of Science ®Google Scholar
• Halasz P, Cramer JA, Hodoba D et al. Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. Epilepsia51(10), 1963–1969 (2010).
   PubMed Web of Science ®Google Scholar
• Vaz-da-Silva M, Nunes T, Almeida L, Gutierrez MJ, Litwin JS, Soares-da-Silva P. Evaluation of eslicarbazepine acetate on cardiac repolarization in a thorough QT/QTc study. J. Clin. Pharmacol. doi:10.1177/0091270010391789 (2011) (Epub ahead of print).
   Google Scholar
• Milovan D, Almeida L, Romach MK et al. Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers. Epilepsy Behav.18(4), 366–373 (2010).
   PubMed Web of Science ®Google Scholar
• Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol. Rep.61(2), 197–216 (2009).
   PubMed Web of Science ®Google Scholar
• Vaz-da-Silva M, Almeida L, Falcao A et al. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study. Clin. Ther.32(1), 179–192 (2010).
   PubMed Web of Science ®Google Scholar
• Rocha JF, Vaz-da-Silva M, Almeida L et al. Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects. Int. J. Clin. Pharmacol. Ther.47(4), 255–261 (2009).
   PubMed Web of Science ®Google Scholar
• Vaz da Silva M, Costa R, Soares E et al. Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. Fundam. Clin. Pharmacol.23(4), 509–514 (2009).
   PubMed Web of Science ®Google Scholar
• Fontes-Ribeiro C, Macedo T, Nunes T et al. Dosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate: randomized, open-label, crossover, single-centre study in healthy volunteers. Drugs RD9(6), 447–454 (2008).
   PubMedGoogle Scholar
• Maia J, Vaz-da-Silva M, Almeida L et al. Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2–093). Drugs RD6(4), 201–206 (2005).
   PubMedGoogle Scholar
• Falcao A, Maia J, Almeida L, Mazur D, Gellert M, Soares-da-Silva P. Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2–093), a new voltage-gated sodium channel blocker. Biopharm. Drug Dispos.28(5), 249–256 (2007).
   PubMed Web of Science ®Google Scholar
• Nunes T, Sicard E, Almeida L et al. Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects. Curr. Med. Res. Opin.26(6), 1355–1362 (2010).
   PubMed Web of Science ®Google Scholar